JP7818405B2 - 炎症性状態を処置するための方法および組成物 - Google Patents

炎症性状態を処置するための方法および組成物

Info

Publication number
JP7818405B2
JP7818405B2 JP2021574932A JP2021574932A JP7818405B2 JP 7818405 B2 JP7818405 B2 JP 7818405B2 JP 2021574932 A JP2021574932 A JP 2021574932A JP 2021574932 A JP2021574932 A JP 2021574932A JP 7818405 B2 JP7818405 B2 JP 7818405B2
Authority
JP
Japan
Prior art keywords
seq
peptide
inflammatory
body weight
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021574932A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020257221A5 (https=
JP2022536797A (ja
JP2022536797A5 (https=
Inventor
ヒーリー，ラウラ・ディー
モニエ，ローラン・オー
グリフィン，ジョン・エイチ
Original Assignee
ザ スクリプス リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スクリプス リサーチ インスティテュート filed Critical ザ スクリプス リサーチ インスティテュート
Publication of JP2022536797A publication Critical patent/JP2022536797A/ja
Publication of JPWO2020257221A5 publication Critical patent/JPWO2020257221A5/ja
Publication of JP2022536797A5 publication Critical patent/JP2022536797A5/ja
Priority to JP2025133519A priority Critical patent/JP2025172264A/ja
Application granted granted Critical
Publication of JP7818405B2 publication Critical patent/JP7818405B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
JP2021574932A 2019-06-18 2020-06-17 炎症性状態を処置するための方法および組成物 Active JP7818405B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025133519A JP2025172264A (ja) 2019-06-18 2025-08-08 炎症性状態を処置するための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962862977P 2019-06-18 2019-06-18
US62/862,977 2019-06-18
PCT/US2020/038036 WO2020257221A1 (en) 2019-06-18 2020-06-17 Methods and compositions for treating inflammatory conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025133519A Division JP2025172264A (ja) 2019-06-18 2025-08-08 炎症性状態を処置するための方法および組成物

Publications (4)

Publication Number Publication Date
JP2022536797A JP2022536797A (ja) 2022-08-18
JPWO2020257221A5 JPWO2020257221A5 (https=) 2023-11-30
JP2022536797A5 JP2022536797A5 (https=) 2023-11-30
JP7818405B2 true JP7818405B2 (ja) 2026-02-20

Family

ID=74040112

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021574932A Active JP7818405B2 (ja) 2019-06-18 2020-06-17 炎症性状態を処置するための方法および組成物
JP2025133519A Withdrawn JP2025172264A (ja) 2019-06-18 2025-08-08 炎症性状態を処置するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025133519A Withdrawn JP2025172264A (ja) 2019-06-18 2025-08-08 炎症性状態を処置するための方法および組成物

Country Status (6)

Country Link
US (1) US20220313780A1 (https=)
EP (2) EP4461303A3 (https=)
JP (2) JP7818405B2 (https=)
CN (1) CN114258317B (https=)
AU (1) AU2020295989A1 (https=)
WO (1) WO2020257221A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120518705A (zh) * 2025-07-23 2025-08-22 中国海洋大学 一种多肽类化合物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510988A (ja) 1996-10-30 2001-08-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プロテアーゼ活性化受容体３およびその使用
JP2005531311A (ja) 2002-06-28 2005-10-20 ファイザー・インク 改変型ｐａｒ受容体、その調製およびｐａｒ活性調節化合物のスクリーニングへのその使用
WO2017173346A1 (en) 2016-04-01 2017-10-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Par3 mimetic peptides and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965343A (en) 1988-01-28 1990-10-23 Hoffmann-La Roche Inc. Method of peptide synthesis
US5849954A (en) 1996-01-18 1998-12-15 Research Corporation Technologies, Inc. Method of peptide synthesis
CN1308671A (zh) * 1998-05-05 2001-08-15 科里克萨公司 髓磷脂碱性蛋白肽及其应用
ATE281472T1 (de) 1999-08-02 2004-11-15 Synt Em Sa Berechnungsmethoden zur herstellung von molekularen mimetika
US7271256B2 (en) 2000-02-04 2007-09-18 New England Biolabs, Inc. Method for producing circular or multimeric protein species in vivo or in vitro and related methods
JP4798921B2 (ja) * 2000-03-06 2011-10-19 バイオシーク インコーポレーティッド 機能相同性スクリーニング
US7696168B2 (en) * 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
GB0224013D0 (en) * 2002-10-15 2002-11-27 Oxford Glycosciences Uk Ltd A protein involved in therapy
WO2004056309A2 (en) * 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
AU2006242449A1 (en) 2005-04-29 2006-11-09 (Osi) Eyetech, Inc. VEGF variants
US20080090760A2 (en) 2005-12-09 2008-04-17 Todd Hembrough Compositions and Methods for Inhibiting Cellular Proliferation
CN101801462A (zh) * 2007-07-13 2010-08-11 健泰科生物技术公司 用于癌症、炎性病症和自身免疫性病症的治疗和诊断
WO2013070256A2 (en) * 2011-11-07 2013-05-16 The Scripps Research Institute Protease activated receptor-1 (par1) derived cytoprotective polypeptides and related methods
CN104470943B (zh) * 2012-07-03 2017-07-14 一洋药品株式会社 新肽及其用途
CA3075833C (en) * 2017-09-18 2024-06-11 BH Biotech Pty Ltd Composition comprising withania extract, omega-3 fatty acids and natural product extracts and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510988A (ja) 1996-10-30 2001-08-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プロテアーゼ活性化受容体３およびその使用
JP2005531311A (ja) 2002-06-28 2005-10-20 ファイザー・インク 改変型ｐａｒ受容体、その調製およびｐａｒ活性調節化合物のスクリーニングへのその使用
WO2017173346A1 (en) 2016-04-01 2017-10-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Par3 mimetic peptides and uses thereof

Also Published As

Publication number Publication date
AU2020295989A1 (en) 2022-01-20
US20220313780A1 (en) 2022-10-06
EP4461303A2 (en) 2024-11-13
EP3986560A4 (en) 2023-10-18
JP2022536797A (ja) 2022-08-18
JP2025172264A (ja) 2025-11-21
CN114258317B (zh) 2025-03-14
EP4461303A3 (en) 2025-05-14
EP3986560A1 (en) 2022-04-27
WO2020257221A1 (en) 2020-12-24
CN114258317A (zh) 2022-03-29

Similar Documents

Publication Publication Date Title
US20230192765A1 (en) Peptides targeting shp2 and uses thereof
US9284362B2 (en) α/β-peptide mimics of Z-domain peptides
AU2013262630B2 (en) Huwentoxin-IV variants and methods of use
US11965039B2 (en) Compstatin analogues and their medical uses
EP2904003A1 (en) Cell penetrating peptides which bind irf5
US20230287051A1 (en) Inhibitors of complement factor c3 and their medical uses
ES3049784T3 (en) Compstatin analogues and their medical uses
JP2025172264A (ja) 炎症性状態を処置するための方法および組成物
AU2018383633B2 (en) Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides
AU2009253623A1 (en) A soluble tumor necrosis factor receptor mutant
EP4137502A1 (en) Vipr2 antagonist peptide
CN120380008A (zh) Psd-95的新颖环肽抑制剂
TW201920235A (zh) 肽pac1拮抗劑
CN121038802A (zh) TNF-α结合剂及其使用方法
US20220153792A1 (en) Peptide Inhibitors Targeting The CXCL12/HMGB1 Interaction And Uses Thereof
CN118440151A (zh) 一种多肽及其在制备抗癌药物中的应用
CN110655583A (zh) 一类新的Bcl10聚合抑制剂及其应用
Gellman et al. αβ-PEPTIDE MIMICS OF Z-DOMAIN PEPTIDES
HK40008797B (zh) 用於治疗骨相关疾病的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250808

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260209

R150 Certificate of patent or registration of utility model

Ref document number: 7818405

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150